1 active not recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Molly Gallogly: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP) - Graft Versus Host Disease | Phase 2 | Withdrawn | Molly Gallogly | 2024-10-01 | 2025-01-07 | |
| Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Venetoclax, Rituximab, Ifosfamide - Diffuse Large B-cell-lymphoma | Phase 1 / Phase 2 | Active not recruiting | Molly Gallogly | 65 | 2017-06-26 | 2022-11-16 |
Dendritic Cell Sarcoma, Interdigitating (1) · Graft vs Host Disease (1)
Carboplatin (1) · Etoposide (1) · Ifosfamide (1) · Photopheresis (1) · Rituximab (1) · venetoclax (1)
United States (2)